AgeingPROMETHEUSNCT07451496
PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)
A study testing Sleep and dietary counseling, Supervised exercise and exergaming program and Motivational interviewing in people with Ageing, run by National University of Singapore at 1 site in Singapore.
Trial summary
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. Read more about this study
- Who is it for?
- Ages 50 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Ageing
- What is being tested?
- Sleep and dietary counseling, Supervised exercise and exergaming program and Motivational interviewing
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSingapore
- Study dates
- 29 Sep 2025to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age 50-80 years (both male and female)
- Relatively healthy and in stable health condition
- Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)
- VO₂peak below the 75th percentile for age- and sex-specific norms
- Cognitive performance below 75th percentile on the NIH Toolbox Cognitive Function Battery
- Willing and able to comply with exercise and supplementation protocols
Show all 10Show fewer
- English-literate (can read and understand English)
- Provides written informed consent
- Deemed to have mental capacity, as assessed by the Principal Investigator
- Are able to attend all research visits for screening and research data collection at MD11, Yong Loo Lin School of Medicine, National University of Singapore
Who cannot join
- Significant change in medication in the past 3 months
- History of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke)
- More than two unstable chronic conditions (e.g., hypertension, diabetes, osteoarthritis, COPD)
- Known allergies to soy, shellfish/seaweed, mushrooms, or supplement ingredients
- Participation in another interventional clinical trial
- Current use of any study-related supplement unless willing to stop
Show all 9Show fewer
- Any medical, psychiatric, or cognitive condition deemed by the PI to jeopardise safety or compliance
- Pregnant or planning pregnancy during the study period
- Any conditions deemed by PI that jeopardize the safety or study compliance
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
MD11 Clinical Research Centre, #03-01, 10 Medical Drive, Singapore 117597
Singapore, Singapore, 117597
Ajla Hodzic Kuerec, MD, PhD, 87142730, ahkuerec@nus.edu.sg
Mazzarine Dotou, PhD, MBA, mazzarine@nus.edu.sg
About this study
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens.
Emerging research highlights several interconnected hallmarks of aging, such as mitochondrial dysfunction, chronic inflammation, impaired autophagy, and immune dysregulation, as modifiable through targeted interventions. Precision geromedicine represents a paradigm shift in addressing these processes, combining baseline diagnostics with individualized treatment strategies that adapt over time based on patient response. This approach integrates lifestyle modifications, dietary supplements, and pharmacological agents to optimize physical, cognitive, and immune function across the lifespan .
Read the detailed description
This study aims to evaluate the effectiveness and feasibility of a personalized, multimodal precision geromedicine intervention targeting key hallmarks of aging. We hypothesize that an 8-week intervention combining lifestyle modification and targeted supplementation will improve biological and clinical markers of aging in middle-aged to older (50-80 years) adults.
Participants within this age range are chosen because they are more likely to encounter early declines in muscle, immune, and cognitive functions, while still being responsive to preventive measures. The criteria for inclusion concentrate on individuals scoring below the 75th percentile for normative values in VO₂peak and cognitive performance. This demographic presents an optimal opportunity for interventions aimed at prolonging healthspan and postponing functional decline.
Hypothesis
The multimodal precision geromedicine intervention will be feasible to conduct and effective in improving muscle, cognitive, and immune function, as well as other biological, clinical, and digital biomarkers of aging in middle aged to older adults.
- Conditions
- Ageing
- Being tested
- Sleep and dietary counseling, Supervised exercise and exergaming program, Motivational interviewing, Whey protein, Creatine Monohydrate
- Keywords
- Whey Protein supplementation, Creatine, Fucoidan, NMN, Multivitamin, Ergothioneine, Urolithin A, Aging, Geroscience, DNA methylation, Healthspan, Epigenetic aging clock
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sleep and dietary counselingOther
Sleep hygiene education and individualized dietary recommendations delivered throughout the intervention period.
Supervised exercise and exergaming programOther
Supervised dual-task cognitive-physical training with an exergaming component conducted three times per week, 60 minutes per session.
Motivational interviewingBehavioural
Structured motivational interviewing sessions aimed at improving adherence to lifestyle and supplementation interventions conducted two times throughout the study.
Whey proteinDietary supplement
Daily whey protein supplementation (GOLD STANDARD 100% ISOLATE, Optimum Nutrition) provided using a standard 30 g scoop (~25 g protein). Dosage based on body weight:
40-59 kg: 1 scoop/day
60-89 kg: 1.5 scoops/day
≥90 kg: 2 scoops/day
Creatine MonohydrateDietary supplement
Daily creatine supplementation (Micronized Creatine Monohydrate, Optimum Nutrition; 1.25 g per capsule). Dosage based on body weight:
40-59 kg: 4 capsules/day
60-89 kg: 6 capsules/day
≥90 kg: 8 capsules/day
FucoidanDietary supplement
Daily fucoidan supplementation (SIRT6Activator®, DoNotAge.org) at a dose of 2.4 g/day.
Urolithin ADietary supplement
Participants below the 50th percentile for normative muscle mass receive urolithin A (StanYouth™ Urolithin A, Bonerge) at 250 mg/day.
Nicotinamide Mononucleotide (NMN)Dietary supplement
Participants below the 50th percentile for normative VO₂peak receive NMN (AbinoNutra® NMN, Abinopharm, Inc.) at 300 mg/day.
MultivitaminDietary supplement
Participants below the 50th percentile for normative cognitive performance receive a gender-specific multivitamin (Centrum), 1 tablet daily.
ErgothioneineDietary supplement
At the midpoint of the intervention (1 month), participants may receive ergothioneine (Dr.Ergo® L-ergothioneine) at 25 mg three times per week based on individual response.
| Study group | Role | What they receive |
|---|---|---|
| 1 Fundamental intervention | Experimental | Participants receive a multimodal lifestyle intervention including sleep optimization, dietary counseling, supervised exercise with an exergaming component, motivational interviewing, and baseline nutritional supplementation. Receives: Other: Sleep and dietary counseling; Other: Supervised exercise and exergaming program; Behavioral: Motivational interviewing; Dietary Supplement: Whey protein; Dietary Supplement: Creatine Monohydrate; Dietary Supplement: Fucoidan |
| 2 Augmented intervention | Experimental | Participants receive the fundamental intervention and additional personalized supplements based on baseline muscle mass, cardiorespiratory fitness, and cognitive performance, with possible mid-study adjustment. Receives: Other: Sleep and dietary counseling; Other: Supervised exercise and exergaming program; Behavioral: Motivational interviewing; Dietary Supplement: Whey protein; Dietary Supplement: Creatine Monohydrate; Dietary Supplement: Fucoidan; Dietary Supplement: Urolithin A; Dietary Supplement: Nicotinamide Mononucleotide (NMN); Dietary Supplement: Multivitamin; Dietary Supplement: Ergothioneine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in cardiorespiratory fitness (VO₂peak)
VO₂peak will be determined using standardized cardiopulmonary exercise testing on an electronically braked cycle ergometer
Measured: Baseline, Week 4, and Week 8
Change from baseline in muscle strength (one-repetition maximum (1RM))
Change from baseline in muscle strength assessed by one-repetition maximum (1RM) testing
Measured: Baseline, Week 4, and Week 8
Change from baseline in muscle mass (Ultrasound imaging)
Muscle thickness of the thigh will be assessed non-invasively using B-mode ultrasound with a linear array transducer.
Measured: Baseline, Week 4, and Week 8
Change from baseline in cognitive performance (NIH Toolbox Fluid Cognition Composite)
Change from baseline in cognitive performance assessed by the NIH Toolbox Fluid Cognition Composite score.
Measured: Baseline, Week 4, and Week 8
Change from baseline in immune function (CD4+: CD8+ ratio)
Change from baseline in immune status assessed by the CD4+:CD8+ T-cell ratio.
Measured: Baseline, Week 4, and Week 8
Secondary outcomes (20)
Change from Baseline in Circulating Cytokines, Chemokines, and Growth Factors
Change from baseline in circulating cytokines, chemokines, and growth factors. These will be quantified in plasma using enzyme-linked immunosorbent assays (ELISA) or multiplex immunoassays based on xMAP technology. Concentrations will be expressed in standard units (e.g., pg/mL)
Measured: Baseline, Week 4, and Week 8
Change from baseline in advanced glycation end-products
Change from baseline in tissue advanced glycation end-products (AGEs), assessed using skin autofluorescence.
Measured: Baseline, Week 4, and Week 8
Change from baseline in methylation levels
Genome-wide DNA methylation levels will be measured using Illumina BeadChips, which will be scanned on the iScan System. Methylation levels will be quantitatively determined from the fluorescence signals.
Measured: Baseline, Week 4, and Week 8
Change from baseline in blood multi-omics profiles
Blood-based multi-omics profiles, including proteomics and lipidomics, will be assessed using standard analytical platforms.
Measured: Baseline, Week 4, and Week 8
Change from baseline in gut microbiome composition and fuctional capacity
Gut microbiome composition and functional capacity will be characterized using short-read shotgun metagenomic sequencing of DNA extracted from stool samples. Changes from baseline to Week 8 will be assessed at the species and functional gene levels.
Measured: Baseline and Week 8
Change from Baseline in Body Composition (Fat and Lean Mass)
Body composition, including fat mass and lean mass, will be assessed using bioelectrical impedance analysis.
Measured: Baseline, Week 4, and Week 8
Change from Baseline in Arterial Stiffness (Carotid-Femoral Pulse Wave Velocity)
Carotid-femoral pulse wave velocity (cf-PWV) will be measured using applanation tonometry at the carotid artery combined with a thigh cuff.
Measured: Baseline, Week 4, and Week 8
Change from baseline in sleep quality
Sleep quality will be assessed using validated questionnaires, including the Pittsburgh Sleep Quality Index (PSQI) and the SATED questionnaire, as well as objective sleep metrics collected via the Oura Ring wearable device. Changes from baseline to each follow-up time point will be reported.
Measured: Baseline, Week 4, and Week 8
Change from baseline in skin color and elasticity
Skin color and elasticity will be assessed using a standardized colorimeter
Measured: Baseline, Week 4, and Week 8
Change from baseline in oral health indicators
Oral health status and mucosal condition will be assessed using validated questionnaires, including the Geriatric Oral Health Assessment Index (GOHAI) and the Modified CDC/AAP oral health questionnaires.
Measured: Baseline, Week 4, and Week 8
Change from baseline in reproductive health
Reproductive health will be assessed using validated questionnaires. For men, the Androgen Deficiency in Aging Males (ADAM) and Brief Sexual Function Inventory (BSFI) will be used; for women, the Female Sexual Function Index (FSFI) will be used.
Measured: Baseline, Week 4, and Week 8
Change from Baseline in Waist and Hip Circumferences
Waist and hip circumferences will be measured using a standardized measuring tape.
Measured: Baseline, Week 4, and Week 8
Change from Baseline in Blood Pressure (Systolic and Diastolic)
Brachial systolic and diastolic blood pressures will be measured using an automated cuff.
Measured: Baseline, Week 4, and Week 8
Change from baseline in Physical activity levels
Physical activity will be objectively measured using the Oura Ring wearable device, which passively tracks daily steps, activity intensity, and sleep duration throughout the intervention period.
Measured: Baseline, Week 4, and Week 8
Change from Baseline in Quality of Life
Quality of life will be assessed using the 36-Item Short Form Survey (SF-36) and EuroQol-5D-5L (EQ-5D).
Measured: Baseline, Week 4, and Week 8
Change from baseline in Psychological Well-being
Exhaustion will be evaluated using two items from the Center for Epidemiologic Studies Depression Scale (CES-D). Depression, anxiety, and stress levels will be measured using the 21-item Depression Anxiety and Stress Scale (DASS-21).
Measured: Baseline, Week 4, and Week 8
Change from baseline in wellness
Overall wellness will be assessed using a validated wellness questionnaire.
Measured: Baseline, Week 4, and Week 8
Change from baseline in food intake
Participants will record dietary intake using a 3-day food diary. Changes from baseline in nutrient and energy intake will be analyzed.
Measured: Baseline, Week 4, and Week 8
Change from Baseline in Grip Strength
Grip strength will be measured using a hand-held dynamometer (Jamar Plus+).
Measured: Baseline, Week 4, and Week 8
Change from Baseline in Standard Clinical Blood Biomarkers
Standard clinical blood tests, including hematology, liver and renal function profiles, lipid profile, glucose, HbA1c, insulin, and high-sensitivity C-reactive protein (hs-CRP), will be conducted by an accredited clinical laboratory.
Measured: Baseline, Week 4, and Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study start29 Sep 2025
- Primary completion23 Feb 2026
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AgeingStudies of the same condition, open and under way.
- More trials run by National University of SingaporeThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This is an open-label, single arm interventional feasibility study in which 20 participants (aged 50 to 80 years) will receive an 8-week multimodal precision geromedicine intervention.
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Singapore
- Sponsor type
- University, hospital or other
- Collaborators
- Xprize Foundation, Abinopharm, Inc, DoNotAge.org
- Responsible party
- Principal investigator, Andrea Maier, National University of Singapore
- Investigators
- Prof. Andrea Britta Maier, MD, PhD, Principal investigator, National University of Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07451496
- Sponsor's protocol ID
- NUS-IRB-2025-393
- Acronym
- PROMETHEUS
- Status last verified
- Feb 2026
- First submitted
- 16 Dec 2025
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) underlying the primary, secondary and other outcome measures reported in this study, will be made available on request. Data will be fully de-identified and will not include direct identifiers. Raw multi-omics data (e.g., DNA methylation, proteomics, lipidomics, microbiome sequencing) may be shared in processed or aggregated form, as appropriate, to minimize re-identification risk.
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)
- ClinicalTrials.gov ID
- NCT07451496
- Acronym / sponsor ID
- PROMETHEUS / NUS-IRB-2025-393
- Conditions
- Ageing
- Keywords
- Whey Protein supplementation, Creatine, Fucoidan, NMN, Multivitamin, Ergothioneine, Urolithin A, Aging
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- National University of SingaporeUniversity, hospital or other
- Collaborators
- Xprize Foundation, Abinopharm, Inc, DoNotAge.org
- Study start
- 29 Sep 2025 (actual)
- Primary completion
- 23 Feb 2026 (actual)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens.
Emerging research highlights several interconnected hallmarks of aging, such as mitochondrial dysfunction, chronic inflammation, impaired autophagy, and immune dysregulation, as modifiable through targeted interventions. Precision geromedicine represents a paradigm shift in addressing these processes, combining baseline diagnostics with individualized treatment strategies that adapt over time based on patient response. This approach integrates lifestyle modifications, dietary supplements, and pharmacological agents to optimize physical, cognitive, and immune function across the lifespan .
Detailed description
This study aims to evaluate the effectiveness and feasibility of a personalized, multimodal precision geromedicine intervention targeting key hallmarks of aging. We hypothesize that an 8-week intervention combining lifestyle modification and targeted supplementation will improve biological and clinical markers of aging in middle-aged to older (50-80 years) adults.
Participants within this age range are chosen because they are more likely to encounter early declines in muscle, immune, and cognitive functions, while still being responsive to preventive measures. The criteria for inclusion concentrate on individuals scoring below the 75th percentile for normative values in VO₂peak and cognitive performance. This demographic presents an optimal opportunity for interventions aimed at prolonging healthspan and postponing functional decline.
Hypothesis
The multimodal precision geromedicine intervention will be feasible to conduct and effective in improving muscle, cognitive, and immune function, as well as other biological, clinical, and digital biomarkers of aging in middle aged to older adults.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is an open-label, single arm interventional feasibility study in which 20 participants (aged 50 to 80 years) will receive an 8-week multimodal precision geromedicine intervention.
| Arm | Type | Receives |
|---|---|---|
| 1 Fundamental intervention | Experimental | Other: Sleep and dietary counseling, Other: Supervised exercise and exergaming program, Behavioral: Motivational interviewing, Dietary Supplement: Whey protein, Dietary Supplement: Creatine Monohydrate, Dietary Supplement: FucoidanParticipants receive a multimodal lifestyle intervention including sleep optimization, dietary counseling, supervised exercise with an exergaming component, motivational interviewing, and baseline nutritional supplementation. |
| 2 Augmented intervention | Experimental | Other: Sleep and dietary counseling, Other: Supervised exercise and exergaming program, Behavioral: Motivational interviewing, Dietary Supplement: Whey protein, Dietary Supplement: Creatine Monohydrate, Dietary Supplement: Fucoidan, Dietary Supplement: Urolithin A, Dietary Supplement: Nicotinamide Mononucleotide (NMN), Dietary Supplement: Multivitamin, Dietary Supplement: ErgothioneineParticipants receive the fundamental intervention and additional personalized supplements based on baseline muscle mass, cardiorespiratory fitness, and cognitive performance, with possible mid-study adjustment. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Age 50-80 years (both male and female)
- Relatively healthy and in stable health condition
- Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)
- VO₂peak below the 75th percentile for age- and sex-specific norms
- Cognitive performance below 75th percentile on the NIH Toolbox Cognitive Function Battery
Key exclusion criteria (9 listed)
- Significant change in medication in the past 3 months
- History of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke)
- More than two unstable chronic conditions (e.g., hypertension, diabetes, osteoarthritis, COPD)
- Known allergies to soy, shellfish/seaweed, mushrooms, or supplement ingredients
- Participation in another interventional clinical trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sleep and dietary counselingSleep hygiene education and individualized dietary recommendations delivered throughout the intervention period. | Other | 1 Fundamental intervention, 2 Augmented intervention |
| Supervised exercise and exergaming programSupervised dual-task cognitive-physical training with an exergaming component conducted three times per week, 60 minutes per session. | Other | 1 Fundamental intervention, 2 Augmented intervention |
| Motivational interviewingStructured motivational interviewing sessions aimed at improving adherence to lifestyle and supplementation interventions conducted two times throughout the study. | Behavioural | 1 Fundamental intervention, 2 Augmented intervention |
| Whey proteinDaily whey protein supplementation (GOLD STANDARD 100% ISOLATE, Optimum Nutrition) provided using a standard 30 g scoop (~25 g protein). Dosage based on body weight: 40-59 kg: 1 scoop/day 60-89 kg: 1.5 scoops/day ≥90 kg: 2 scoops/day | Dietary supplement | 1 Fundamental intervention, 2 Augmented intervention |
| Creatine MonohydrateDaily creatine supplementation (Micronized Creatine Monohydrate, Optimum Nutrition; 1.25 g per capsule). Dosage based on body weight: 40-59 kg: 4 capsules/day 60-89 kg: 6 capsules/day ≥90 kg: 8 capsules/day | Dietary supplement | 1 Fundamental intervention, 2 Augmented intervention |
| FucoidanDaily fucoidan supplementation (SIRT6Activator®, DoNotAge.org) at a dose of 2.4 g/day. | Dietary supplement | 1 Fundamental intervention, 2 Augmented intervention |
| Urolithin AParticipants below the 50th percentile for normative muscle mass receive urolithin A (StanYouth™ Urolithin A, Bonerge) at 250 mg/day. | Dietary supplement | 2 Augmented intervention |
| Nicotinamide Mononucleotide (NMN)Participants below the 50th percentile for normative VO₂peak receive NMN (AbinoNutra® NMN, Abinopharm, Inc.) at 300 mg/day. | Dietary supplement | 2 Augmented intervention |
| MultivitaminParticipants below the 50th percentile for normative cognitive performance receive a gender-specific multivitamin (Centrum), 1 tablet daily. | Dietary supplement | 2 Augmented intervention |
| ErgothioneineAt the midpoint of the intervention (1 month), participants may receive ergothioneine (Dr.Ergo® L-ergothioneine) at 25 mg three times per week based on individual response. | Dietary supplement | 2 Augmented intervention |
Primary outcome
Change from baseline in cardiorespiratory fitness (VO₂peak)
Time frame: Baseline, Week 4, and Week 8
VO₂peak will be determined using standardized cardiopulmonary exercise testing on an electronically braked cycle ergometer
Change from baseline in muscle strength (one-repetition maximum (1RM))
Time frame: Baseline, Week 4, and Week 8
Change from baseline in muscle strength assessed by one-repetition maximum (1RM) testing
Change from baseline in muscle mass (Ultrasound imaging)
Time frame: Baseline, Week 4, and Week 8
Muscle thickness of the thigh will be assessed non-invasively using B-mode ultrasound with a linear array transducer.
Change from baseline in cognitive performance (NIH Toolbox Fluid Cognition Composite)
Time frame: Baseline, Week 4, and Week 8
Change from baseline in cognitive performance assessed by the NIH Toolbox Fluid Cognition Composite score.
Change from baseline in immune function (CD4+: CD8+ ratio)
Time frame: Baseline, Week 4, and Week 8
Change from baseline in immune status assessed by the CD4+:CD8+ T-cell ratio.
20 secondary outcomes
Change from Baseline in Circulating Cytokines, Chemokines, and Growth Factors
Time frame: Baseline, Week 4, and Week 8
Change from baseline in advanced glycation end-products
Time frame: Baseline, Week 4, and Week 8
Change from baseline in methylation levels
Time frame: Baseline, Week 4, and Week 8
Change from baseline in blood multi-omics profiles
Time frame: Baseline, Week 4, and Week 8
Change from baseline in gut microbiome composition and fuctional capacity
Time frame: Baseline and Week 8
Change from Baseline in Body Composition (Fat and Lean Mass)
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Arterial Stiffness (Carotid-Femoral Pulse Wave Velocity)
Time frame: Baseline, Week 4, and Week 8
Change from baseline in sleep quality
Time frame: Baseline, Week 4, and Week 8
Change from baseline in skin color and elasticity
Time frame: Baseline, Week 4, and Week 8
Change from baseline in oral health indicators
Time frame: Baseline, Week 4, and Week 8
Change from baseline in reproductive health
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Waist and Hip Circumferences
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Blood Pressure (Systolic and Diastolic)
Time frame: Baseline, Week 4, and Week 8
Change from baseline in Physical activity levels
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Quality of Life
Time frame: Baseline, Week 4, and Week 8
Change from baseline in Psychological Well-being
Time frame: Baseline, Week 4, and Week 8
Change from baseline in wellness
Time frame: Baseline, Week 4, and Week 8
Change from baseline in food intake
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Grip Strength
Time frame: Baseline, Week 4, and Week 8
Change from Baseline in Standard Clinical Blood Biomarkers
Time frame: Baseline, Week 4, and Week 8
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) underlying the primary, secondary and other outcome measures reported in this study, will be made available on request. Data will be fully de-identified and will not include direct identifiers. Raw multi-omics data (e.g., DNA methylation, proteomics, lipidomics, microbiome sequencing) may be shared in processed or aggregated form, as appropriate, to minimize re-identification risk.
Related trials for Ageing
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
RecruitingObservational study
Effects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults
Obesity, Sarcopenic Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Prof. Andrea Britta Maier, MD, PhD principal investigator
National University of Singapore
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sleep and dietary counseling, Supervised exercise and exergaming program and Motivational interviewing in people with Ageing, run by National University of Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ajla Hodzic Kuerec, MD, PhD (+65 91686091, ahkuerec@nus.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in cardiorespiratory fitness (VO₂peak) (time frame: Baseline, Week 4, and Week 8). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.